Updates to Gastroesophageal Reflux Disease and H. pylori Eradication

29 Jan Updates to Gastroesophageal Reflux Disease and H. pylori Eradication

All TreatGx users now have access to the updated treatment algorithms for Gastroesophageal Reflux Disease (GERD) and H. pylori Eradication. The GERD algorithm provides pharmacotherapy options for adults with mild/intermittent or moderate-severe GERD symptoms, and treatment options for pregnancy. The H. pylori Eradication algorithm provides pharmacotherapy options for adults who have tested positive for H. pylori infection, with or without endoscopy confirmation. Both algorithms incorporate the latest treatment guideline recommendations.

Based on the 2020 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline update for CYP2C19 and proton pump inhibitor (PPI) dosing [1], the pharmacogenetic information has been updated for the PPIs included in the GERD and H. pylori eradication algorithms that are affected by genetic variations in CYP2C19 metabolizer status.

In addition to the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions, the GERD update includes clear stepwise instructions based on treatment guidelines for moderate to severe GERD when a previous trial of a standard-dose PPI has been ineffective. The H. pylori Eradication update includes a simplified and streamlined approach to displaying treatment options to allow clinicians to choose from a selection of medication combinations and regimens, as well as updated and comprehensive drug dosing information.

References

1. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DLet al:Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther 2020.